NCT05555615 Phase 2, phase 3 Terminated
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder Study sponsor: ACADIA Pharmaceuticals Inc. · ACAD
Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.
Changes Study details Primary completion 2025-02-14 Actual
Enrollment · participants 209 Actual
Source updated 2025-12-03 Last update listed in the registry record
Version history
Changes to this trial Last 12 months Posted 2025-11-14 · 1 field changed
Primary outcomes · main study measures Text edit · unverified significance − Previous value measure: Treatment-emergent adverse events
+ Updated value measure: Treatment-emergent Adverse Events
The saved outcome text may be shortened. Check the source for full wording.
Check registry source This database covers selected trials and recorded edits. Some past edits may be missing, and saved text about the main study measures (endpoints) may be shortened. Check the original registry record when a detail matters. Read our methodology
Trial